TNF and inflammatory bowel disease: Patients with IBD treated with anti-TNF exhibit lower frequencies of replacement VH mutations in CDR1-3 compared with patients with IBD treated with anti-IL-12/23 after dose 2 and 3, and lower mutation frequencies in CDR1 compared with people in the healthy control group after dose 3 (Figure 6C).